AbbVie (NYSE:ABBV) is performing well this year. The company's shares have climbed 26% on the back of a strong financial performance. Further, the pharmaceutical giant's medium-term outlook appears bright. AbbVie has no significant loss of patent exclusivity remaining this decade, and its two growth pillars, Skyrizi and Rinvoq, are firing on all cylinders. Still, AbbVie is already thinking about succession plans for its most important medicines, and recent developments suggest the company is well on its way to finding new drugs to pass the torch to. Image source: The Motley Fool.
CryptoAlerta — análise de criptomoedas e mercado em tempo real